We have looked at the broader obesity landscape but what else can data tell us about the what is coming. This becomes even more difficult because the obesity field is now moving fast enough that static competitive landscapes become outdated almost immediately after publication. Topline datasets are increasingly disclosed through investor presentations, conference abstracts, earnings […]
May 7th Update- Obesity Market Part 2
I wanted to follow up on the obesity market analysis because it leads to a question as to what is next. I will focus on the early clinical stage and highlight two. I would not make a definitive claim that these are the best but they stand out and the more important part is how […]
May 6th, Obesity Market Analysis
This is a different post in that I am going to be focusing on proprietary data and analysis. Below is summary of the findings and then I will talk more generally about the data. This should be of value and if there are particular ways in which you would like to see the data or […]
May 5th Biotech Update
I am going to try and get back into a consistent rhythm in writing and want to jump right into the most important news of the day. The ACACIA-HCM study from CYTK was designed as a randomized, double-blind, placebo-controlled Phase 3 trial evaluating aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy. The population largely […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
